阿尔茨海默病血液标志物参考区间的研究进展OA
Research progress on reference intervals for blood markers of Alzheimer disease
阿尔茨海默病血液标志物检测因其无创性、可及性和成本低而备受关注.其中,血液β淀粉样蛋白(Aβ)、磷酸化tau蛋白亚型和胶质纤维酸性蛋白等标志物在阿尔茨海默病的诊断、治疗监测和预后判断中显示出良好的应用前景.但由于人种、检验系统、方法学、人群筛选标准等存在差异,目前尚无国际公认的参考区间标准.本文系统总结了Aβ40、Aβ42、磷酸化tau181、磷酸化tau217等核心血液标志物参考区间的研究进展,探讨了建立我国人群阿尔茨海默病血液标志物参考区间面临的问题.
Blood biomarkers for Alzheimer disease have attracted significant research attention because of their noninvasive nature,accessibility,and low cost.Among these,blood biomarkers such as amyloid β-protein(Aβ),phosphorylated tau protein subtypes,and glial fibrillary acidic protein have exhibited promising application prospects in the diagnosis,treatment monitoring,and prognosis assessment of Alzheimer disease.However,owing to differences in ethnicity,testing systems,methodologies,and population screening criteria,no internationally recognized reference interval standard currently exists.This study systematically reviews the research progress on reference intervals for core blood standards,such as Aβ40,Aβ42,phosphorylated tau181,and phosphorylated tau217,and discusses the current chal-lenges in establishing reference intervals for the Chinese population.
王梦婷;赵敏
中国医科大学附属第一医院检验科,沈阳 110001中国医科大学附属第一医院检验科,沈阳 110001
医药卫生
阿尔茨海默病血液标志物参考区间
Alzheimer diseaseblood markerreference interval
《中国医科大学学报》 2026 (5)
454-459,6
国家重点研发计划"主动健康和人口老龄化科技应对"重点专项(2022YFC3062302)
评论